Detection of minimal residual disease (MRD) has helped to improve the treatment of patients with leukemia. At present MRD testing in patients with multiple myeloma (MM) is not applied as a standard diagnostic or prognostic method.
Dept. of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany. fenk@med.uni-duesseldorf.de